MIDAS (Modafinil in Debilitating Fatigue After Stroke)

MIDAS (Modafinil in Debilitating Fatigue After Stroke)

BACKGROUND AND PURPOSE This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke. We hypothesized that 200 mg of modafinil daily for 6 weeks would result in reduced symptoms of fatigue compared with placebo. METHODS This single-center phase 2 trial used a randomized, double-blind, placebo-controlled, crossover...

Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial

BACKGROUND Fatigue is a common symptom in stroke survivors for which there is currently no proven therapy. Modafinil is a wakefulness-promoting agent with established benefits in other disease models. We aim to test if modafinil will improve patient's self-reported fatigue scores when compared to placebo and if therapy results in increased quality of life. METHODS/DESIGN MIDAS is a phase II, ...

Fatigue after stroke

Modafinil for fatigue in multiple sclerosis.

atigue is a perplexing and at times incapacitating symptom in multiple sclerosis. It has both physical and cog-nitive components and its severity is not closely related to the extent of neurologi-cal disability, nor to clinical or laboratory measures of inflammatory activity, nor to depression. 1 2 Treatment is unsatisfactory, with few controlled studies and with interpretation of results hinde...

Model of understanding fatigue after stroke.

F atigue is ubiquitous but it is more common and more severe in patients with acute and chronic conditions, including stroke. The reported proportion of people with fatigue after stroke ranges from 23% to 75%. 1 The variation in proportion between studies reflects the heterogeneity in the studied populations , time since stroke, and assessment methods for fatigue. Fatigue is common immediately ...